Full Length Research Paper
References
|
Abubakar MS, Musa AM, Ahmed A, Hussaini IM (2007). The perception and practice of traditional medicine in the treatment of cancers and inflammations by the Hausa and Fulani tribes of Northern Nigeria. J Ethnopharmacol. 111:625-629. Crossref |
||||
|
Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD (2004). Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J. Neuropathol. Exp. Neurol. 63(7):700-707. Pubmed |
||||
|
Amos S, Martin PM, Polar GA, Parsons SJ, Hussaini IM (2005). Phorbol 12-Myristate 13-Acetate Induces Epidermal Growth Factor Receptor Transactivation via Protein Kinase C/c-Src Pathways in Glioblastoma Cells. J. Biol. Chem. 280(9):7729–7738. Crossref |
||||
|
Balunas MJ, Kinghorn AD (2005). Drug discovery from medicinal plants. Life Sci. 78(5):431-441. Crossref |
||||
|
Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A (2009). Therapeutic targets in malignant glioblastoma microenvironment. Semin. Radiat. Oncol. 19:163-170. Crossref |
||||
|
Chang L, Su J, Jia X, Ren H (2014). Treating malignant glioma in Chinese patients: update on temozolomide. Onco. Targets Ther. 7:235-244. Pubmed |
||||
|
Chu C, Everiss K, Wikstrand C, Batra S, Kung H, Bigner D (1997). Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. 324:855-861. Pubmed |
||||
|
Corson TW, Crews CM (2007). Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130(5):769-774. Crossref |
||||
|
Gan HK, Cvrljevic AN, Johns TG (2013). The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 280(21):5350-5370. Crossref |
||||
|
Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25:55-57. Crossref |
||||
|
Hu K, Dong A, Sun Q, Tao X (2001). Bioactivity of 247 Traditional Chinese Medicines against Pyricularia oryzae. Pharm. Biol. 39(1):47–53 Crossref |
||||
|
Huse JT, Holland EC (2010). Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer. 10:319-33. Crossref |
||||
|
Hussaini IM, Karns LR, Vinton G, Carpenter J.E, Redpath GT, Sando JJ, VandenBerg SR (2000). Phorbol 12-myristate 13-acetate induces protein kinase ceta-specific proliferative response in astrocytic tumor cells. J. Biol. Chem. 275(29):22348-54. Crossref |
||||
|
Kaskiw MJ, Tassotto ML, Moka M, Tokar SL, Pycko R, Th'ng J, Jiang Z (2009). Structural analogues of diosgenyl saponins: Synthesis and anticancer activity. Bioorg. Med. Chem. Lett. 17(22):7670-7679. Crossref |
||||
|
Mischel PS, Cloughesy TF (2003). Targeted molecular therapy of GBM. Brain Pathol. 13:52-61. Crossref |
||||
|
Miyamoto K, Murayama T, Nomura M, Hatano T, Yoshida T, Furukawa T, Koshiura R, Okuda T (1993). Antitumor activity and interleukin-1 induction by tannins. Anticancer Res. 13(1):37-42. Pubmed |
||||
| Neuwinger JD (translated from the German by Porter A) (1996). African ethnobotany-poisons and drugs. Chapman and Hall, Weinheim, Germany pp. 495-499. | ||||
|
Ohgaki H, Schauble B, Zur H, von Ammon K, Kleihues P (1995). Genetic alterations associated with the Evolution of Astrocytic Brain tumours. Virchows Arch. 427:113-118. Crossref |
||||
|
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS (2014). The epidemiology of glioma in adults: a "state of the science" review. Neuro. Oncol. 16(7):896-913. Crossref |
||||
|
Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, MacDonald JM, Yung WKA, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker II FG, Buckner JC, James CD, Aldape K (2007). Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J. Clin. Oncol. 25(16):2288-2294. Crossref |
||||
|
Rao RD, Uhm JH, Krishnan S, James CD (2003). Genetic and signaling pathway alterations in glioblastoma: Relevance to novel targeted therapies. Front. Biosci. 8:e270-280. Crossref |
||||
|
Reardon DA, Wen PY (2006). Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. Oncologist 11:152-164. Crossref |
||||
| Reardon DA, Wen PY, Mellinghoff IK (2014). Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro-oncology 16(suppl 8):viii7-viii13. | ||||
|
Ren W, Qiao Z, Wang H, Zhu L, Zhang L (2003). Flavonoids: promising anticancer agents. Med. Res. Rev. 23(4):519-534. Crossref |
||||
|
Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, MacGehee-Norman S, Paolino A, Reardon DA, Fiedman AH, FriedmanHS, Bigner DD (2009). An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 8(10): 2773-2779. Crossref |
||||
|
Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y (2003). Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63(20):6962-6970. Pubmed |
||||
| Shoeb M (2006). Anticancer agents from medicinal plants. Bangladesh J. Pharmacol. 1(2):35-41. | ||||
|
Silva GL, Lee I, Kinghorn AD (1998). Special problems with the extraction of plants. In: Cannell RJP (ed) Methods in Biotechnology (Natural product Isolation). Humana press, New Jersey pp. 245-364. Crossref |
||||
| Soladoye MO, Amusa NA, Raji-Esan SO, Chukwuma EC, Taiwo AA (2010). Ethnobotanical Survey of Anti-Cancer Plants in Ogun State, Nigeria. Annu. Biol. Res. 1(4):261-273. | ||||
|
Stevigny C, Bailly C, Quetin JL (2005). Cytotoxic and antitumor potentialities of aporphinoid alkaloids. Curr. Med. Chem-Anti-Cancer Agents, 5:173-182. Crossref |
||||
|
Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl. J. Med. 352(10):987-996. Crossref |
||||
|
Tatematsu H, Mori M, Yang TH, Chang JJ, Lee Th TY, Lee KH (1991). Cytotoxic principles of Securinega virosa: virosecurininie and viroallosecurinine and related derivatives. J. Pharm. Sci. 80:325-327. Crossref |
||||
|
Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL (2014). Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiol. Biomarkers Prev. 23(10):1985-1996. Crossref |
||||
|
Tsuruo T, Oh-hara T, Iida H, Tsukagoshi S, Sato Z, Matsuda I, Iwasaki S, Okuda S, Shimizu F, Sasagawa K, Fukami M, Fukuda K, Arakawa M (1986). Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res. 46:381-385. Pubmed |
||||
|
van der Geer P, Hunter T, Linberg RA (1994). Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell. Biol. 10:251-337 Crossref |
||||
|
Zahonero C, Sánchez-Gómez P (2014). EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. Cell Mol. Life Sci. pp.1-24. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
